ST香雪：TAEST16001临床试验已明确肿瘤抗原表达检测标准

Core Viewpoint - The company confirmed that the clinical trial protocol for TAEST16001 includes clear standards for tumor antigen expression detection in target patients, but does not utilize organoid models for patient screening or efficacy validation [1] Group 1 - The clinical trial for TAEST16001 is a TCR-T cell therapy targeting tumor antigens [1] - The company has established specific criteria for detecting tumor antigen expression in patients during the Phase II clinical trial [1] - No organoid models or similar technologies are employed for patient selection or efficacy validation in the related studies [1]